Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 4/2005

01-04-2005

SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C

Authors: Masashi Naito, Atsushi Matsui, Mie Inao, Sumiko Nagoshi, Makoto Nagano, Nobuko Ito, Tohru Egashira, Michie Hashimoto, Shunji Mishiro, Satoshi Mochida, Kenji Fujiwara

Published in: Journal of Gastroenterology | Issue 4/2005

Login to get access
Metadata
Title
SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C
Authors
Masashi Naito
Atsushi Matsui
Mie Inao
Sumiko Nagoshi
Makoto Nagano
Nobuko Ito
Tohru Egashira
Michie Hashimoto
Shunji Mishiro
Satoshi Mochida
Kenji Fujiwara
Publication date
01-04-2005
Publisher
Springer-Verlag
Published in
Journal of Gastroenterology / Issue 4/2005
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-005-1558-3

Other articles of this Issue 4/2005

Journal of Gastroenterology 4/2005 Go to the issue

Case report

Usefulness of recombinant Em18-ELISA to evaluate efficacy of treatment in patients with alveolar echinococcosis

OriginalPaper

Superparamagnetic iron oxide-enhanced MR imaging for focal hepatic lesions: a comparison with CT during arterioportography plus CT during hepatic arteriography

OriginalPaper

Duodenum is important for the sphincter of Oddi motor response to cholecystokinin octapeptide in conscious dogs

Letters to the editor

Refractory enterovesical and duodenocolic fistulas in Crohn’s disease successfully managed with tacrolimus

Rapid communication

Osteopontin expression in ulcerative colitis is distinctly different from that in Crohn’s disease and diverticulitis

OriginalPaper

A high peripheral microvessel density count correlates with a poor prognosis in pancreatic cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits